Drug Profile

Sapanisertib - Takeda Oncology

Alternative Names: CB-228; FTH-003; HY-13328; INK-128; MLN-0128; TAK-228

Latest Information Update: 28 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Intellikine
Developer Calithera Biosciences; Dana-Farber Cancer Institute; European Network for Translational Research in Ovarian Cancer (EUTROC); M. D. Anderson Cancer Center; National Cancer Institute (USA); Stanford University School of Medicine; Takeda; Takeda Oncology
Class Antineoplastics; Benzoxazoles; Pyrazolones; Pyrimidines; Small molecules
Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Phase II Bladder cancer; Cancer; Endometrial cancer; Fallopian tube cancer; Glioblastoma; Neuroendocrine tumours; Ovarian cancer; Peritoneal cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Soft tissue sarcoma; Thyroid cancer; Urogenital cancer
Phase I/II Liver cancer; Merkel cell carcinoma; Sarcoma
Preclinical Leukaemia
No development reported Non-small cell lung cancer; Solid tumours
Discontinued HER2 negative breast cancer; Multiple myeloma; Prostate cancer; Renal cell carcinoma; Triple negative breast cancer; Waldenstrom's macroglobulinaemia

20 Oct 2025 Updated efficacy data from a phase II trial in Endometrial cancer released by Millennium Pharmaceuticals
19 Oct 2025 Efficacy and adverse events data from a phase II trial in Ovarian cancer and Fallopian tube cancer released by Faeth Therapeutics
19 Oct 2025 Faeth Therapeutics plans a phase III trial for Ovarian cancer (Combination therapy)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com